Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 12 Days Payable is 29.05 as of Dec. 2025, which is 43% below its 10-year median of 50.80. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Bionet Therapeutics ranks worse than 72.04% on this metric.
The historical rank and industry rank for Bionet Therapeutics's Days Payable or its related term are showing as below:
ROCO:7808'
s Days Payable Range Over the Past 10 Years
Min: 43.07 Med: 50.8 Max: 302.24
Current: 43.07
During the past 4 years, Bionet Therapeutics's highest Days Payable was 302.24. The lowest was 43.07. And the median was 50.80.
ROCO:7808's Days Payable is ranked worse than 72.04% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs ROCO:7808: 43.07
Bionet Therapeutics's Days Payable
declined
from Dec. 2024 (64.64) to Dec. 2025 (29.05).
It may suggest that Bionet Therapeuticsaccelerated paying its suppliers.
Bionet Therapeutics Days Payable Related Terms
Bionet Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Bionet Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bionet Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionet Therapeutics (ROCO:7808) has a Days Payable of 29.05 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bionet Therapeutics and its competitors. This is 43% below median its historical median of 50.80. Over the past decade, Bionet Therapeutics' Days Payable has ranged from 43.07 to 302.24. According to the industry distribution chart, Bionet Therapeutics ranks #505 out of 701 companies in the Biotechnology industry, placing it in the top 72%.
Is Bionet Therapeutics' Days Payable too high?
Bionet Therapeutics' current Days Payable of 29.05 is 43% below median its 10-year median of 50.80. Over the past 10 years, this metric has ranged from a low of 43.07 to a high of 302.24. The Biotechnology industry median Days Payable is 112.84. Bionet Therapeutics' value of 29.05 is 74.3% below this industry median. Based on the distribution chart, Bionet Therapeutics ranks #505 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #505 out of 701 companies for Days Payable. This places Bionet Therapeutics in the lower half of its industry. The industry median Days Payable is 112.84. Bionet Therapeutics' value of 29.05 is 74.3% below this benchmark. Historically, Bionet Therapeutics' own Days Payable has ranged from 43.07 to 302.24 over the past decade. While the company's 10-year median is 50.80 vs. the industry median of 112.84, Bionet Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet Therapeutics's current Days Payable of 29.05 is 74.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current Days Payable is 29.05, which is 43% below median its own 10-year median of 50.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Days Payable of 29.05. The current Days Payable is 29.05, which is 43% below median its 10-year median of 50.80 and 74.3% below the Biotechnology industry median of 112.84. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Days Payable is 29.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score
Get the complete analysis for ROCO:7808
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
